Compliance is one of the reasons our budget increase was necessary, but we are also, as I've said several times, just completing a very long and complicated guidelines review process, which has involved not only public hearings but the issuance of notices of hearings and the evaluation of comments.
We have had meetings with the Canadian generic drug association, BIOTECanada, and Rx&D. We have a committee. We have had five meetings with Rx&D, which is the main innovative organization. All of this is coming to an end in June, so that part of our excessive workload is hopefully going to stop.